1	
2	
3	
4	Glucose and lipid profiles in men with non-obstructive
5	azoospermia
6	
7	
8	Ponco Birowo ¹ *, Dimas Tri Prasetyo ¹ , Dwi Ari Pujianto ² , Widi Atmoko ¹ , Nur
9	Rasyid ¹
10	
11	
12	
13	¹ Department of Urology, Faculty of Medicine Universitas Indonesia - Dr. Cipto
14	Mangunkusumo Hospital, Jakarta
15	
16	² Department of Medical Biology, Faculty of Medicine Universitas Indonesia,
17	Jakarta
18	
19	* Corresponding author
20	Email: ponco.birowo@gmail.com

21 Running title: Glucose and lipid profiles in men with non-obstructive azoospermia

22 Abstract

23 The impact of a low testosterone level among men with non-obstructive 24 azoospermia with various testicular histopathological patterns on the regulation of 25 glucose and lipid metabolism is less well known than among the general population. 26 The aim of this retrospective study was to examine the association between 27 testicular histopathology and components of the metabolic profile among men with 28 non-obstructive azoospermia. Participants were divided into two groups: men with 29 non-obstructive azoospermia and men with obstructive azoospermia. Testicular 30 biopsies were performed among those with non-obstructive azoospermia. We 31 included 115 patients in this study: 83 (72.2%) had non-obstructive azoospermia 32 and 32 (27.8%) had obstructive azoospermia. The plasma glucose concentration, 33 glycated hemoglobin level, and lipid profile were similar between patients with 34 non-obstructive azoospermia and those with obstructive azoospermia. Upon 35 subgroup analysis of patients with non-obstructive azoospermia, those with Sertoli-36 cell-only syndrome had the lowest testosterone (431 \pm 238 ng/dL; *P*=0.039) and 37 highest follicle-stimulating hormone (23.4 \pm 18.2 mIU/mL; P=0.002) 38 concentrations. They also had the highest triglyceride concentration (163 \pm 114 39 mg/dL; P=0.001). Interestingly, patients with Sertoli-cell-only syndrome had a 40 lower fasting plasma glucose concentration ($92 \pm 11 \text{ mg/dL}$; P < 0.001) and glycated 41 hemoglobin level ($5.9 \pm 0.8\%$; P=0.022) than those with histopathological patterns 42 of maturation arrest and hypospermatogenesis. In conclusion, differences in

43 glucose and lipid metabolism are evident between men with non-obstructive44 azoospermia with different spermatogenesis patterns.

45

46 Key Words: azoospermia; NOA; OA; serum testosterone; metabolic profile.

47

48 Introduction

The association between testosterone and the development of type-2 diabetes mellitus (DM), obesity, and dyslipidemia has been demonstrated [1–6]. Testosterone deficiency is reportedly related to metabolic syndrome [7]. The exact mechanism by which testosterone may affect the metabolic profile is yet to be established.

Testosterone is thought to have protective effects against the pathogenesis of metabolic syndrome and its components by increasing skeletal muscle tissue and decreasing abdominal obesity and the levels of nonesterified fatty acids in the body [8]. Testosterone reportedly has a favorable effect on vascular reactivity, inflammation, cytokine production, and the expression of adhesion molecules, as well as on the serum lipid concentration and hemostatic factors [9].

Despite the fact that there have been numerous studies in which the association between testosterone and the metabolic profile has been investigated, its effect on the regulation of glucose and lipid metabolism in infertile men with non-obstructive azoospermia (NOA), particularly in relation to testicular

64	histopathology, is less well known. Thus, the aim of this study was to examine the
65	effect of testosterone level on the plasma glucose and lipid profiles of men with
66	NOA, as well as its impact based on testicular histopathology patterns. We revealed
67	that the presence of testicular damage in NOA is associated with lower serum
68	testosterone and higher levels of follicle-stimulating hormone (FSH), as well as
69	lower fasting plasma glucose and higher triglyceride levels than the absence of such
70	damage.

71

72 Material and methods

73 **Patient selection**

74 In this retrospective study, we included all men with azoospermia seeking infertility 75 treatment at the Urology Clinics of Dr. Cipto Mangunkusumo Hospital and Bunda 76 Hospital (Jakarta, Indonesia) from 2016 to 2020. Azoospermia is defined as the 77 absence of spermatozoa in the seminal fluid after centrifugation. The diagnosis was 78 made only when no spermatozoa was found in two consecutive semen analyses, each 79 after 2-7 days of sexual abstinence. Patients who were recruited into this study did not 80 have any prior history of type-2 DM or dyslipidemia and did not take any medication 81 that may affect glucose or lipid metabolism in the 3 months before recruitment. Patients 82 were excluded if had any prior history of type-2 DM, dyslipidemia, and taking any 83 medication that may affect glucose or lipid metabolism in the 3 months before

84 recruitment. Type-2 DM is defined as 1) having a fasting plasma glucose concentration 85 of \geq 126 mg/dL, or 2) 2-hour plasma glucose \geq 200 mg/dL (11.1 mmol/L) during oral 86 glucose tolerance test, or 3) A1C >6.5% (48 mmol/mol), or 4) experiencing classical 87 symptoms of hyperglycemia or hyperglycemic crisis (polyuria or polydipsia) and 88 having a random plasma glucose concentration ≥200 mg/dL [10]. Dyslipidemia is 89 defined as a history of exhibiting either a total cholesterol concentration $\geq 200 \text{ mg/dL}$, 90 a high-density lipoprotein (HDL) cholesterol concentration <40 mg/dL for men and 91 <50 mg/dL for women, or a triglyceride concentration >150 mg/dL [11]. There were 92 two study groups in this study: patients with NOA and those with obstructive 93 azoospermia (OA). The NOA/OA diagnosis was based on the patient history, clinical 94 examination, and reproductive hormone (follicle-stimulating hormone [FSH], 95 luteinizing hormone, and testosterone) assessment, and confirmed in a testicular 96 histopathology specimen taken during sperm retrieval procedures. This study was 97 approved by the Ethics Committee of the Faculty of Medicine, Universitas Indonesia 98 and complies with the Code of Ethics of the World Medical Association (Declaration 99 of Helsinki 1964, revised 20033 and Declaration of Tokyo 1975, revised 20064). 100 Informed consent from participants were not required due to retrospective data 101 collection.

102

103 Study design

104 We conducted hormonal and metabolic evaluations of all participants, which 105 included concentrations of serum testosterone, serum FSH, fasting plasma glucose, 106 glycated hemoglobin (HbA1c), total cholesterol, low-density lipoprotein (LDL), high-107 density lipoprotein (HDL), and triglyceride. Participants were asked to fast for 10-12 h 108 before their blood was drawn. Serum testosterone was examined by using an 109 electrochemiluminescence immunoassav (Roche, Basel, Switzerland). Serum FSH was 110 examined by using immunochemiluminescence (Siemens Healthineers, Erlangen, 111 Germany). Fasting plasma glucose was measured by using the hexokinase method 112 (Diatron Promedika, Jakarta, Indonesia). HbA1c was examined by using an enzymatic 113 assay (Abbott Architect, Illinois, USA). Total cholesterol was measured by using the 114 cholesterol oxidase-peroxidase aminoantipyrine technique, LDL and HDL were 115 examined by using homogeneous assays, and triglyceride was measured by using 116 glycerol peroxidase phosphate method (all reagents for lipid profiling were from 117 Diatron Promedika). The serum testosterone concentration was presented as 118 nanograms/deciliter (ng/dL), the FSH concentration was presented as milli-119 international units per milliliter (mIU/mL), while the fasting plasma glucose, total 120 cholesterol, LDL cholesterol, HDL cholesterol, and triglyceride concentrations were 121 presented as milligrams/deciliter (mg/dL). HbA1c was presented as a percentage (%). 122

123 **Testicular biopsy**

We also performed surgical sperm retrieval by using testicular sperm extraction (TESE) for patients with NOA as a part of their infertility treatment. TESE was performed by making a small incision on the avascular plane of the testis and collecting a small portion of the testicular tissue for examination for the presence of motile spermatozoa under an electric light microscope.

129 We also performed a second testicular biopsy for histological examination of the 130 testicular phenotype (spermatogenesis pattern). Samples were added into a Bouin's 131 solution and sent to the laboratory for examination. In the laboratory, several sections 132 of the samples were prepared and stained in paraffin blocks. The section with the 133 highest concentration of seminiferous tubules was examined by the same laboratory 134 analyst for all samples under a light microscope. Testicular histopathological patterns 135 were divided into three categories (Fig 1): (i) Sertoli cell only (SCO; absence of germ 136 cells in the seminiferous tubules), (ii) maturation arrest (incomplete spermatogenesis), 137 and (iii) hypospermatogenesis (a reduced number of normal spermatogenic cells). All 138 sperm retrieval and testicular biopsy procedures were performed by the same surgeon, 139 while all testicular histopathological examinations in this study were performed in the 140 same laboratory by the same examiner.

141

142 Fig 1. Classification of spermatogenesis based on testicular histopathological

143 patterns. A. Sertoli cell only (#). B. Maturation arrest with spermatocyte cells (\$). C.

144 Hypospermatogenesis, which is marked by a decreased number of normal

spermatozoa (^). Courtesy of the Department of Biology, Faculty of Medicine,

146 Universitas Indonesia, Jakarta.

147

148 Statistical analysis

149 All continuous data were presented as mean and standard deviation value as it met 150 the normality distribution assumption by using Shapiro-Wilk test. No outlier was 151 removed from the analysis. We compared the results of the hormonal and metabolic 152 evaluations between patients with NOA and those with OA by using the two-tailed 153 independent t-test. We performed subgroup analysis within the NOA group based on 154 the testicular histopathological patterns by using one-way analysis of variance and 155 post-hoc Bonferroni test. Minimum sample size is 30 for each group based on 156 hypothesis testing for two mean formula (power 80%, alpha 5%) [12]. All statistical 157 analyses were performed by using IBM SPSS Statistics for Windows version 20.0 158 (IBM Corp., Armonk, NY, USA) [13], with P<0.05 considered statistically significant. 159

160 **Results**

We included 115 patients in this study, of which 83 (72.2%) were in the NOA group and 32 (27.8%) were in the OA group. The age range of patients was 26-72 years and there were no significant differences in age or body mass index between the two study groups (Table 1).

165

166 Table 1. Comparisons of hormonal and metabolic parameters between patients

167 with NOA and those with OA

Parameter	NOA (n = 83)	OA (n = 32)	P value
Age (years)	36 ± 7	38 ± 9	0.308 / t = 1.024
BMI (kg/m ²)	26.7 ± 5.4	27.7 ± 5.5	0.632 / t = 0.483
Serum testosterone (ng/dL)	442 ± 181	511 ± 126	0.049 / t = 1.970
FSH (mIU/mL)	16.3 ± 13.8	4.3 ± 1.1	<0.001 / t = -4.879
Fasting plasma glucose (mg/dL)	98 ± 32	90 ± 10	0.143 / t = -1.476
HbA1c (%)	6.1 ± 1.4	5.4 ± 0.4	0.132 / t = -1.534
Total cholesterol (mg/dL)	203 ± 34	197 ± 53	0.462 / t = -0.738
LDL (mg/dL)	143 ± 38	159 ± 44	0.240 / t = 1.188
HDL (mg/dL)	42.8 ± 9.1	43.9 ± 8.5	0.574 / t = 0.564
Triglyceride (mg/dL)	145 ± 81	124 ± 44	0.159 / t = -1.417

168 *P* values were calculated with the two-tailed independent t-test and degree of freedom 113 All results are presented

169 as the mean \pm standard deviation.

170 NOA = non-obstructive azoospermia; OA = obstructive azoospermia; BMI = body mass index; FSH = follicle-

171 stimulating hormone; HbA1c = glycated hemoglobin; HDL = high-density lipoprotein; LDL = low-density

172 lipoprotein.

174	Patients with NOA had significantly lower serum testosterone and higher FSH
175	concentrations compared to those with OA (Table 1). Furthermore, no significant
176	differences were observed in glucose and lipid profiles between the two study groups.
177	Among patients with NOA, patients with SCO testicular histopathology had the lowest
178	serum testosterone (431 ± 238 ng/dL; P =0.039) and highest FSH (23.4 ± 18.2 mIU/mL;
179	P=0.002) concentrations (Table 2). Patients with SCO had a lower total cholesterol
180	than those with maturation arrest and hypospermatogenesis (185 \pm 29 mg/dL, 208 \pm 35
181	mg/dL, and 215 \pm 31 mg/dL, respectively; <i>P</i> =0.008). A comparison of LDL levels
182	among those groups yielded similar results (122 \pm 25, 160 \pm 18, and 146 \pm 8,
183	respectively; P=0.012).

184

185 Table 2. Comparisons of hormonal and metabolic parameters among patients

100 with NOA based on testicular histopathological patter	186	with NOA based on testicula	ar histopathological patter	ns
---	-----	-----------------------------	-----------------------------	----

Parameter	SCO (n = 24)	Maturatio n arrest (n = 40)	Hypospermatogenes is (n = 19)	P value
Age (years)	34.8 ± 6.5	36.6 ± 7.2	38.8 ± 7.2	0.194
BMI (kg/m ²)	22.7 ± 3.1	29.1 ± 4.9	28.4 ± 6.1	0.141
Serum testosterone (ng/dL)	431 ± 238	441 ± 157	455 ± 152	0.039*

	23.4 ±	14.3 ±		
FSH (mIU/mL)	18.2	11.6	11.8 ± 8.3	0.009**
Fasting plasma glucose				
(mg/dL)	92 ± 11	101 ± 42	102 ± 27	0.559
HbA1c (%)	5.9 ± 0.8	6.2 ± 1.8	6.1 ± 1.7	0.874
Total cholesterol (mg/dL)	185 ± 29	208 ± 35	215 ± 31	0.008***
				0.012***
LDL (mg/dL)	122 ± 25	160 ± 18	146 ± 8	*
HDL (mg/dL)	40.3 ± 8.1	44.5 ± 9.3	42.5 ± 9.4	0.203
Triglyceride (mg/dL)	$1\overline{63 \pm 114}$	$1\overline{41 \pm 68}$	132 ± 51	0.417

187 *Post-hoc analysis (Bonferroni test) significant between SCO and hypospermatogenesis (P = 0.032), **between

188 SCO and maturation arrest (P = 0.028) and SCO and hypospermatogenesis (P = 0.017), ***between SCO and

189 maturation arrest (P = 0.031) and SCO and hypospermatogenesis (P = 0.012), and **** between SCO and

190 maturation arrest (P = 0.010). P values were obtained with one-way analysis of variance. All results are presented

191 as the mean \pm standard deviation.

192 NOA = non-obstructive azoospermia; SCO, Sertoli cell only; BMI = body mass index; FSH = follicle-stimulating

hormone; HbA1c = glycated hemoglobin; HDL = high-density lipoprotein; LDL = low-density lipoprotein.

194

195 **Discussion**

196 We are aware of only a few studies in which the association between male infertility 197 and glucose and lipid metabolism was investigated. Our results revealed that NOA was 198 more common than OA among patients with azoospermia seeking fertility treatment at 199 our center. This is consistent with previous studies, in which a higher incidence of NOA 200 than OA was reported among men with azoospermia [14,15]. FSH and testosterone 201 evaluation are important aspects of the assessment of patients with azoospermia, to, for 202 example, differentiate between NOA and OA. Typically, men with NOA have higher 203 FSH and lower testosterone concentrations and a more abnormal pattern of testicular 204 histopathology than those with OA [16]. Thus, the high FSH and low testosterone 205 values in men with NOA in our study were expected and consistent with the literature. 206 The etiologies of and risk factors for NOA include Klinefelter's syndrome, 207 cryptorchidism, Y-chromosome microdeletion, and Kallmann syndrome [17–19]. The 208 causes of NOA were not investigated in this study.

209 Although not statistically significant, patients with NOA had a higher triglyceride 210 level than those with OA (145 \pm 81 mg/dL vs. 124 \pm 44 mg/dl; P=0.159). This 211 parameter, however, exhibited statistically significant differences among patients with 212 NOA with different patterns of spermatogenesis upon testicular histopathology. A 213 study by Bobjer et al. [20] on patients with hypogonadism and NOA revealed that the 214 testosterone and triglyceride concentrations were positively correlated (P=0.03). 215 Hypertriglyceridemia and a low HDL concentration was also more commonly detected 216 in men with azoospermia and oligospermia than in normal controls in a study by

217 Mendoza et al [21]. Calonge et al. [22] also reported a correlation between triglyceride 218 concentration and infertility, where a higher triglyceride concentration was observed 219 in patients who were infertile compared to controls (164 vs. 91 mg/dL; P<0.01). None 220 of these studies, however, demonstrated a causal relationship between dyslipidemia 221 and azoospermia.

222 Despite the limited data available on the association between male infertility. 223 particularly NOA, and glucose metabolism, many studies have demonstrated a 224 relationship between plasma glucose concentration/development of type-2 DM and 225 hypogonadism. Laaksonen et al. [23], who conducted a cohort study on 702 middle-226 aged Finnish men without a history of type-2 DM or metabolic syndrome, discovered 227 that men with testosterone, free testosterone, and sex hormone-binding globulin 228 concentration in the lower quartile had odds ratios ranging from 1.57 (95% confidence 229 interval [CI]=0.98-2.50 to 2.89 (95% CI=1.93-4.33) for the development of metabolic 230 syndrome after an 11-year follow-up, even after adjusting for age, smoking status, 231 alcohol intake, socioeconomic status, and previous cardiovascular disease. Pitteloud et 232 al. [22], investigating 60 men (age range: 39-65 years) without a history of testicular 233 disorder, discovered that testosterone concentration was correlated with insulin 234 sensitivity. Patients with a low serum testosterone concentration had a threefold higher 235 prevalence of metabolic syndrome compared to patients with normal serum 236 testosterone level (90% vs. 29%). Blouin et al. revealed that the effects of declining 237 dehydroepiandrosterone sulfate, an endogenous androgen, on the metabolic profile 238 were age dependent, unlike those of serum testosterone [24].

There are many other studies in which the association between testosterone and the metabolic profile was examined. However, most of them were focused on the effects of type-2 DM on the testosterone level. Corona et al. [25] conducted a meta-analysis on the association between testosterone and type-2 DM, discovering that patients with type-2 DM exhibited statistically significantly lower concentrations of plasma testosterone than non-diabetic individuals. The same group also revealed that both

type-2 DM and metabolic syndrome were independent predictors of a low testosteroneconcentration [26].

247 In this study, patients with SCO had the lowest testosterone and highest FSH 248 concentrations. This was in accordance with a previous study by Yassin et al. [27], 249 wherein lower testosterone (1.7 \pm 1.3 vs. 5.0 \pm 2.2 ng/mL; P<0.001) and higher FSH 250 $(20.8 \pm 14.8 \text{ vs } 7.7 \pm 3.9 \text{ mIU/mL}; P < 0.001)$ concentrations were found in patients with 251 SCO syndrome (SCOS) than in fertile men. Another study of 134 patients with SCOS 252 also revealed low testosterone ($4.4 \pm 1.6 \text{ ng/mL}$) and high FSH ($18.9 \pm 9.0 \text{ mIU/mL}$) 253 concentrations [28]. Interestingly, in our study, patients with SCOS had higher total 254 cholesterol and LDL concentration than patients with maturation arrest and those with 255 hypospermatogenesis. We are not aware of an existing report to this effect. On the other 256 hand, the triglyceride concentration was higher in patients with the poorest 257 histopathologic pattern (SCO), although statistically not significant. This may indicate 258 that triglyceride metabolism is related to the process of spermatogenesis. Our results 259 regarding glucose and lipid metabolism among patients with NOA with different

patterns of testicular histopathology, however, may not be generalizable, as the number of patients was relatively modest. Thus, further studies on the association between different levels of testicular damage and the metabolic profile are warranted, with larger study samples.

264 In conclusion, the presence of testicular damage in NOA is associated with lower 265 serum testosterone and higher FSH concentrations, as well as with lower total 266 cholesterol and LDL concentrations. Further studies are needed to better explain these 267 phenomena, incorporating larger samples and follow-ups. All the components of 268 metabolic syndrome, i.e., hypertension, hyperglycemia or insulin resistance, large 269 waist circumference, and hypercholesterolemia or hypertriglyceridemia, must also be 270 incorporated in future studies, so that the association between male infertility and the 271 development of metabolic syndrome can be investigated.

272

273 Acknowledgements

274 None.

275

276 **References**

Daubresse JC, Meunier JC, Wilmotte J, Luyckx AS, Lefebvre PJ. Pituitary testicular axis in diabetic men with and without sexual impotence. Diabetes Metab.
 1978;4(4): 233–7.

Hamdan FB, Al-Matubsi HY. Assessment of erectile dysfunction in
 diabetic patients. Int J Androl. 2009;32(2): 176–85.
 Rhoden EL, Ribeiro EP, Teloken C, Souto CA. Diabetes mellitus is
 associated with subnormal serum levels of free testosterone in men. BJU Int.

284 2005;96: 867–70.

4. Kapoor D, Aldred H, Clark S, Channer KS, Jones TH. Clinical and
biochemical assessment of hypogonadism in men with type 2 diabetes: Correlations
with bioavailable testosterone and visceral adiposity. Diabetes Care. 2007;30(4):

288 911–7.

289 5. Phillips GB. Relationship between serum sex hormones and glucose,
290 insulin and lipid abnormalities in men with myocardial infarction. Proc Natl Acad
291 Sci U S A. 1977;74(4): 1729–33.

- 292 6. Haffner SM, Karhapaa P, Mykkanen L, Laakso M. Insulin resistance,
 293 body fat distribution, and sex hormones in men. Diabetes. 1994;43(2): 212–9.
- Z94 7. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen TP, Salonen R, et al. Sex hormones, inflammation and the metabolic syndrome: a
 population-based study. Eur J Endocrinol. 2003;149(6): 601–8.
- 8. Marin P, Holmang S, Jonsson L, Sjostrom L, Kvist H, Holm G, et al.
 The effects of testosterone treatment on body composition and metabolism in
 middle-aged obese men. Int J Obes. 1992;16(12): 991–7.
- 300 9. Corona G, Mannucci E, Forti G, Maggi M. Following the common
 301 association between testosterone deficiency and diabetes mellitus, can testosterone

302	be regarde	ed as a new therapy for diabetes? Int J Androl. 2009;32(5): 431-41.
303	10.	American Diabetes Association. 2. Classification and diagnosis of
304	diabetes: S	Standards of medical care in diabetes-2021. Diabetes Care. 2021;44: S15-
305	33.	
306	11.	Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca
307	VA, Garb	er AJ, et al. American Association of Clinical Endocrinologists and
308	American	College of Endocrinology Guidelines for Management of Dyslipidemia
309	and Preven	ntion of Cardiovascular Disease. Endocr Pract. 2017;23: 1-87.
310	12.	Lemeshow S, Hosmer DW, Klar J, Lwanga SK. Adequacy of Sample
311	Size in He	alth Studies. WHO. West Sussex: John Wiley & Sons, Ltd; 1990.
312	13.	IBM. IBM SPSS Statistics for Windows, Version 20.0. NY: IBM Corp.;
313	2011.	
314	14.	Jarow JP, Espeland MA, Lipshultz LI. Evaluation of the azoospermic
315	patient. J U	Urol. 1989;142(1): 62–5.
316	15.	Hernández Uribe L, Hernández Marín I, Cervera-Aguilar R, Ayala AR.
317	[Frequenc	y and etiology of azoospermia in the study of infertile couples]. Ginecol
318	Obstet Me	ex. 2001;69: 322–6. Spanish.
319	16.	Esteves SC. Clinical management of infertile men with nonobstructive
320	azoospern	nia. Asian J Androl. 2015;17: 459–70.
321	17.	Hamada AJ, Esteves SC, Agarwal A. A comprehensive review of
322	genetics a	nd genetic testing in azoospermia. Clinics. 2013;68(Suppl 1): 39-60.
323	18.	Liu PY, Handelsman DJ. The present and future state of hormonal

treatment for male infertility. Hum Reprod Update. 2003;9(1): 9–23.

325 19. Ramalingam M, Kini S, Mahmood T. Male fertility and infertility. 326 Obstet Gynaecol Reprod Med. 2014;24(11): 326–32. 327 20. Bobjer J, Naumovska M, Giwercman YL, Giwercman A, High 328 prevalence of androgen deficiency and abnormal lipid profile in infertile men with 329 non-obstructive azoospermia. Int J Androl. 2012;35: 688-94. 330 21. Mendoza SG, Osuna A, Zerpa A, Gartside PS, Glueck CJ. 331 Hypertriglyceridemia and hypoalphalipoproteinemia in azoospermic and 332 oligospermic young men: Relationships of endogenous testosterone to triglyceride 333 and high density lipoprotein cholesterol metabolism. Metabolism. 1981;30(5): 481-334 6. 335 22 Calonge RN, Kireev R, Guijarro A et al. L dysregulation in seminal 336 and follicular fluids could be related with male and female infertility. Lipid 337 Dysregulation in Seminal and Follicular Fluids could be Related with Male and 338 Female Infertility. Endocrinol Metab Int J. 2018;6(1): 68-74. 339 23. Laaksonen DE, Niskanen L, Punnonen K, Nyyssonen K, Tuomainen T-340 P, Valkonen V-P, et al. Testosterone and sex hormone-binding globulin predict the 341 metabolic syndrome and diabetes in middle-aged men. Diabetes Care. 2004;27(5): 342 1036-41. 343 Blouin K, Després J-P, Couillard C, Tremblay A, Prud'homme D, 24. 344 Bouchard C, et al. Contribution of age and declining androgen levels to features of 345 the metabolic syndrome in men. Metabolism. 2005;54(8): 1034–1040.

346	25. Corona G, Monami M, Rastrelli G, Aversa A, Sforza A, Lenzi A, et al.
347	Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl.
348	2011;34(6 Pt 1): 528–40.
349	26. Corona G, Monami M, Rastrelli G, Aversa A, Tishova Y, Saad F, et al.
350	Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med. 2011;8(1):
351	272-83.
352	27. Yassin MM, Lubbad AMH, Taha AZ, Laqqan MM, Samar M.
353	Testosterone and Gonadotropins in Infertile Men with Sertoli Cell Only Syndrome
354	from Gaza Strip. J Med. 2017;18(1): 21-6.
355	28. Gul U, Turunc T, Haydardedeoglu B, Yaycioglu O, Kuzgunbay B,
356	Ozkardes H. Sperm retrieval and live birth rates in presumed Sertoli-cell-only
357	syndrome in testis biopsy: a single centre experience. Andrology. 2013;1(1): 47-
358	51.
359	
360	